Skip to main content
HARBIN GLORIA PHARMACEUTICALS Co., LTD logo

HARBIN GLORIA PHARMACEUTICALS Co., LTD — Investor Relations & Filings

Ticker · 002437 ISIN · CNE100000QG8 LEI · 300300K1ZDAXM6M73U33 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,133 across all filing types
Latest filing 2025-05-16 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 002437

About HARBIN GLORIA PHARMACEUTICALS Co., LTD

https://www.gloria.cc

Harbin Gloria Pharmaceuticals Co., Ltd. focuses on the research, development, manufacturing, and commercialization of diverse pharmaceutical products. The company specializes in therapeutic areas including cardiovascular and cerebrovascular diseases, orthopedics, oncology, and metabolic disorders. Its portfolio comprises chemical drugs, biological products, and specialized injections, with key products such as Alprostadil and Deer Melon Polypeptide. The organization prioritizes technological innovation through a dedicated R&D infrastructure aimed at developing both generic and innovative medications. It maintains multiple production facilities and an extensive distribution network to supply healthcare solutions for chronic and acute conditions.

Recent filings

Filing Released Lang Actions
2024年年度股东大会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the legality of the procedures and resolutions of the 2024 Annual General Meeting (AGM) of Harbin Yuheng Pharmaceutical Co., Ltd. It details the convening, attendance, voting procedures, and results of the AGM, including the approval of various agenda items such as the annual report, financial statements, profit distribution, and appointment of auditors. The document does not contain the actual annual report or financial statements but rather certifies the legality and validity of the AGM process and its resolutions. This type of document is typically classified as Declaration of Voting Results & Voting Rights Announcements (DVA) because it officially reports the voting outcomes and confirms the legitimacy of the shareholder meeting proceedings.
2025-05-16 Chinese
2024年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2024年年度股东大会决议公告" which translates to "2024 Annual General Meeting Resolution Announcement." It details the resolutions passed at the 2024 Annual General Meeting (AGM) of the company, including voting results on various proposals such as the annual report, board work report, profit distribution plan, financial report, and appointment of auditors. It also includes information about meeting attendance, legal opinions, and independent director reports. The document is a formal announcement of the voting results and resolutions passed at the AGM, not the full annual report or financial statements themselves. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 5784 characters, which is consistent with a detailed voting results announcement rather than a full report or presentation.
2025-05-16 Chinese
关于使用闲置自有资金进行委托理财的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the progress of using idle self-owned funds for entrusted wealth management products. It includes specifics about various financial products purchased, their terms, risk levels, investment directions, and amounts. The document is dated May 14, 2025, and provides comprehensive information about the company's investment activities in wealth management products, including risk disclosures and impact on the company. It is not a financial report like an annual or interim report, nor is it a certification or a brief announcement. It is a regulatory announcement about capital management activities, specifically about the use of idle funds for entrusted wealth management. This fits best under the category of Capital/Financing Update (CAP), as it updates on the company's financing activities and capital usage. The document length (7195 characters) and detailed content support this classification with high confidence.
2025-05-13 Chinese
关于参加黑龙江辖区上市公司2025年投资者网上集体接待日活动的公告
Investor Presentation Classification · 90% confidence The document is a short announcement (673 characters) about the company's participation in an investor collective reception day event organized by a regional stock association. It mentions interaction with investors regarding the company's 2024 annual and 2025 Q1 performance, governance, strategy, and sustainability. There is no detailed financial data or full report content, only an event notice for investor communication. This fits the category of an Investor Presentation (IP) or a related investor communication event. Given the nature of the event focusing on company performance and strategy discussion with investors, the best fit is Investor Presentation (IP).
2025-05-09 Chinese
关于2024年限制性股票激励计划首次授予部分第一个限售期解除限售股份上市流通的提示性公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the unlocking and listing of restricted shares under the 2024 restricted stock incentive plan. It includes information about the approval process, conditions for unlocking, number of shares unlocked, and changes in share capital structure. The document is not a financial report like an annual or interim report, nor is it a call transcript or earnings release. It is a formal announcement about the lifting of restrictions on stock incentives and the related share circulation. This fits the category of a Regulatory Filing (RNS) because it is a regulatory announcement about share incentive plan details and share circulation, not a report or presentation. The document length is over 5,000 characters and contains substantive content, but it is not a financial report or management report. Therefore, the best classification is Regulatory Filings (RNS).
2025-05-07 Chinese
关于2024年限制性股票激励计划之首次授予部分第一个限售期解除限售事宜的法律意见书
Audit Report / Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the company's 2024 restricted stock incentive plan and the first unlocking of restricted shares after the first lock-up period. It discusses legal compliance, approvals, and conditions for lifting restrictions on stock incentives. It is not a financial report, earnings release, or management discussion. It is a standalone legal opinion related to a specific corporate action (stock incentive plan unlocking). This fits best under Audit Report / Information (AR) as it is a formal legal opinion verifying compliance and conditions related to a corporate financial/legal matter, but not a full annual report or earnings release. The document length (7792 characters) and detailed legal content support this classification. FY 2024
2025-04-25 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.